Radiotherapy (RT) can be used as preoperative treatment to downstage initially unresectable locally rectal carcinoma, but radioresistance and recurrence remain significant problems. Retinoblastoma binding protein 6 (RBBP6) has been implicated in the regulation of cell cycle, apoptosis and chemoresistance both in vitro and in vivo.
Radiotherapy (RT) can be used as preoperative treatment to downstage initially unresectable locally rectal carcinoma, but radioresistance and recurrence remain significant problems. Retinoblastoma binding protein 6 (RBBP6) has been implicated in the regulation of cell cycle, apoptosis and chemoresistance both in vitro and in vivo.
The present study investigated whether the inhibition of RBBP6 expression would improve radiosensitivity in human colorectal cancer cells. After SW620 and HT29 cells were exposed to radiation, the levels of RBBP6 mRNA and protein increased over time in both cells. Moreover, a significant reduction in clonogenic survival and a decrease in cell viability in parallel with an obvious increase in cell apoptosis were demonstrated in irradiated RBBP6-knockdown cells. Transfection with RBBP6
shRNA improved the levels of G2-M phase arrest, which blocked the cells in a more radiosensitive period of the cell cycle. These observations indicated that cell cycle and apoptosis mechanisms may be connected with tumor cell survival following radiotherapy. In vivo, the tumor growth rate of nude mice in the RBBP6-knockdown group was significantly slower than that in other groups. These results indicated that RBBP6 overexpression could resist colorectal cancer cells against radiation by regulating cell cycle and apoptosis pathways, and inhibition of RBBP6 could enhance radiosensitivity of human colorectal cancer.
tremendous advances in cancer screening and treatment in the USA. 1 Surgical resection is thought to be the predominant therapy for the early stage CRC and total mesorectal excision (TME) is the standard surgery for rectal cancer. However, radical surgery is difficult to perform, especially for initially unresectable advanced colon cancer and mid-low rectal cancer. 2 Preoperative radiotherapy is widely used to downstage tumors to lower treatment failure, but the local recurrence and outcome remain variable, which indicates significant differences in tumor response to radiation. [3] [4] [5] [6] Therefore, it is essential to explore the molecular mechanisms of CRC cell survival following irradiation treatment, and, furthermore, there is an urgent need to identify useful molecular targets to improve the response of CRC to local irradiation.
p53 is thought to be mutated in approximately 50% of human malignancies. p53 mutations are found in 5% of adenomas, 50% of malignant polyps and 75% of invasive CRC, with an increasing frequency positively correlating with the extent of malignancy. 7 In addition to DNA damage, p53 is activated by many factors, including chemicals, viruses, oxidation, osmotic pressure and ultraviolet radiation. 8 Acting as a key tumor suppressor, the p53 protein plays an important role in DNA transcription as well as in suppressing the genesis and development of tumors. When DNA damage occurs, p53
causes cell cycle arrest, so that the cells have enough time to repair DNA damage. If the cells fail to repair DNA damage, p53 will activate the apoptotic pathway to maintain the integrity of chromosomal DNA. 9 Cyclin-dependent kinases (CDK), formed at particular stages of the cell cycle progression, are responsible for regulating critical checkpoints involved in the G2/M and G1/S phase transitions. 10 Activation of p53 drives the expression of many Cyclin Dependent Kinase inhibitors (CDKi), especially for p21. p21, as a crucial inhibitory factor for CDK, can block the cell cycle in the G2 phase by inhibiting the M phase checkpoint CyclinB1/CDK1 complex.
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Retinoblastoma binding protein 6 (RBBP6) gene, located on chromosome 16p22.2, is also referred to as PACT, P2P-R or RBQ-1.
Three major transcripts (transcript 6.1, 6.0 and 1.1 kb), encoding proteins of 1792, 1758 and 118 amino acids, respectively, are expressed by the RBBP6 gene as a consequence of alternative splicing. 12 RBBP6 has been found to be highly expressed in esophagus cancer, lung cancer, breast cancer and cervical cancer, [13] [14] [15] suggesting that RBBP6 may play an important role in the progression of human malignant tumors. RBBP6 is a multi-domain protein that interacts with p53 and Rb using its ring finger domain. It promotes the ubiquitination and degradation of p53 protein through its E3 ubiquitin ligase activity. Due to its ability to bind the tumor suppressors p53 and Rb, it has been proposed that RBBP6 plays a key role in cell cycle, cell proliferation, apoptosis and chemoresistance. [16] [17] [18] Knockdown of RBBP6 expression enhanced the chemosensitivity of lung and breast cancer and resulted in the inhibition of tumor growth. However, in colorectal cancer patients who receive adjuvant radiotherapy before tumor resection, the role of RBBP6 remains unclear.
RBBP6 has an important function in the development and progression of cancer. The aim of the present study was to evaluate whether RBBP6 can influence the sensitivity of colorectal cancer cells to radiotherapy, and to determine whether the RBBP6 gene is a useful biomarker for guiding irradiation treatment before curative resection of colorectal cancer. In a previous study, 19 
| Apoptosis assay

| Immunohistochemical analysis for RBBP6
HT29 tumors were harvested and fixed in formalin. Immunohistochemistry analysis was performed following the standard protocol as previously described. 19 
| Statistical analysis
All data are presented as mean AE SD. The significance of the experimental values was determined using Student t test (2-tailed).
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Differences with a P < .05 were considered statistically significant.
All the statistical analyses were done using SPSS 19.0 statistical software (SPSS, Chicago, IL, USA).
3 | RESULTS
| Irradiation induced upregulation of RBBP6 expression
To investigate the role of RBBP6 in mediating sensitivity to colorectal cancer radioresistance, 4 human colorectal cancer cell lines were used to determine the radiotherapy effect. As the CCK-8 assays
showed, all cells' viability was reduced by radiation treatment in a dose-dependent manner; SW480 and HCT8 cells seem to be more sensitive to radiation than SW620 and HT29 cells ( Figure 1A ). Western blot showed that the expression of RBBP6 in SW620 and HT29 cells was higher than that in SW480 and HCT8 cells ( Figure 1B ).
Radiation treatment was performed in SW620 and HT29 cell lines.
Following 10 Gy of irradiation, the mRNA levels of RBBP6 increased over time in both SW620 and HT29 cells ( Figure 1C ). RBBP6 protein levels were also altered after radiation treatment, which was similar to our qPCR data ( Figure 1D ).
| Effect of shRNA on expression of RBBP6
To determine whether RBBP6 can increase radioresistance in colorectal cancer cells, we silenced RBBP6 by shRNA. Both SW620
RBBP6-KD and HT29 RBBP6-KD stable cell lines were generated (Figure 2 ).
| Inhibition of RBBP6 decreased cell viability
To determine how RBBP6 inhibition affects cell viability and proliferation, CCK-8 assay was performed following 10 Gy of irradiation for 0, 24, 48 or 72 hours or 5 doses of irradiation (0, 2, 4, 6 and 10 Gy) for 48 hours. As a result, RBBP6-KD cell lines showed a significant reduction in cell viability for all 3 incubation times (24, 48 and 72 hours) compared to control cells ( Figure 3A ).
Moreover, cell viability was reduced by radiation treatment in a dose-dependent manner ( Figure 3B ). These data indicated that RBBP6 contributed to radioresistance in SW620 and HT29 cells and targeted inhibition of RBBP6 sensitized these cells to radiation treament.
| Inhibition of RBBP6 decreased clonogenic survival
To further analyze the radiosensitizing ability of RBBP6 inhibition, the clonogenic survival assay was performed after treatment with radiation in SW620 and HT29 cell lines. Lower survival curves were demonstrated in RBBP6-KD cells compared to the control cells (Figure 4) . After silencing RBBP6, the survival rate was significantly decreased in SW620 and HT29 cell lines. In agreement with the above results, we observed after RT an increased activation of Caspase 3, which is known to cleave PARP in RBBP6-KD cell lines compared to the control cells ( Figure 6C ). We also determined the expression of anti-apoptotic mitochondrial proteins Bcl-2, Bcl-XL and pro-apoptotic mitochondrial protein BAX.
The expression of BAX was significantly increased and Bcl-2 and
Bcl-XL were decreased after RT in HT29-KD cells and SW620-KD cells compared to the control cells ( Figure 6C) . Furthermore, the expression of cell cycle checkpoint protein Cyclin B1/Cdk1 was decreased after RT in RBBP6-KD cell lines compared to the control cells ( Figure 6D ).
| Inhibition of RBBP6 led to both cell apoptosis and cycle arrest through attenuating the p53/MDM2 interaction
We further investigated the mechanisms of increased cell apoptosis and cycle arrest following RBBP6 silencing. By western blotting, we observed a significant increase in the level of p53 protein and p21 protein in both cells silenced of RBBP6 relative to control cells. In contrast, the level of Rb protein was not affected ( Figure 7A ). Acting as a tumor suppressor, p53 plays an important role in regulating cell apoptosis and cycle progression.
p21 is a negative regulator of cell cycle, which affects cycle arrest at G1 and G2 through multiple mechanisms. Therefore, we conclude that p53 protein levels in RBBP6-KD cells are higher than those in the control cells. Probably, this is the major reason for the difference in cell apoptosis and cell cycle progression after silencing RBBP6.
We next explored the mechanism of elevated expression of p53 protein in the absence of RBBP6. p53 is antagonized primarily by murine double minute 2 (MDM2), which can promote the 
| DISCUSSION
To the best of our knowledge, this is the first report confirming that overexpression of RBBP6 endows colorectal cancer cells with resistance to apoptosis, which may compromise the therapeutic efficacy of preoperative radiotherapy. RBBP6 expression seemed to be a predictive molecular marker for radiation response and inhibition of RBBP6 could enhance the radiosensitivity of human colorectal cancer.
High expression of RBBP6 protein has been found to be related to cell cycle arrest, decreased apoptosis, and increased chemoresistance in breast cancer, lung cancer and cervical cancer. [13] [14] [15] Our previous study showed that RBBP6 expression was higher in colorectal cancer samples than that of the adjacent noncancerous tissue and RBBP6 overexpression was correlated with recurrence and a poor survival rate. 19 We provided clinical evidence of high expression of RBBP6 in promoting the progression of colon cancer.
Based on the above evidence, in the present study, we investigated whether RBBP6 plays a key role in regulating radiation resistance.
As our present results showed, RBBP6 was significantly upregulated after irradiation in both SW620 and HT29 cells. Therefore, we hypothesized that RBBP6 may be related to the radiotherapy sensitivity of colorectal cancer.
To further clarify the role of RBBP6 in radiotherapy, a shRNA strategy was applied to silence RBBP6 in radioresistant SW620 and patients, especially for patients with low rectal cancer. 26 However, the rates of local and systemic recurrence vary significantly after radiotherapy, which illustrates that progression and resistance remain common events. [27] [28] [29] Preoperative chemoradiotherapy results in fewer than 50% of rectal cancer patients achieving complete pathological response. 30 Response to radiation is considered to be a key factor in the success of radiotherapy, but the response to radiation is determined by multifactorial etiologies (tumor pathologic type, tumor volume, tumor hypoxia, clinical stage, radiation dose and radiation modes). 31, 32 Until now, no valid radiosensitizing target has been unambiguously identified to have prognostic or predictive value for colorectal cancer radiotherapy, although a few potential molecular markers, including EGFR, KRAS/NRAS, BRAF, PTEN and PIK3CA, have been investigated; 33,34 the role they played in radiotherapy remains to be elucidated. In the present study, we observed that Apoptosis is the primary mechanism for the death of colorectal cancer cells induced by radiotherapy. 35, 36 In the course of radiotherapy, several apoptotic signaling pathways could be involved and the resistance to radiation may result from disruption of the pathways. 37, 38 In this study, RBBP6 inhibition obviously increased the extent of cell apoptosis after irradiation treatment, supporting an anti-apoptotic function of RBBP6. To further explore the possible mechanism by which RBBP6 promotes apoptosis evasion and radioresistance, we used western blot analysis to examine the expression of PARP and Caspase-3. As the results showed, in RBBP6-KD cells exposed to radiation, compared with control cells, significantly more cleaved Caspase-3 and cleaved PARP were demonstrated. This indicates that inhibition of RBBP6 expression may contribute to the induction of apoptosis through caspasedependent pathways.
In summary, our results proposed that RBBP6, as demonstrated in pretreatment biopsies, could serve as a molecular biomarker for identifying patients likely to respond to preoperative radiotherapy.
Inhibiting the overexpression of RBBP6 in tumors can improve the therapeutic effect of radiotherapy for colorectal cancer. The underlying mechanisms of anti-RBBP6 strategies for improving the radiation sensitivity of colorectal cancer appear to be multifaceted, and involve alterations in cell cycle distribution as well as regulation of caspase-dependent apoptosis. Based on the data, we hypothesize that RBBP6 may be involved in radiosensitivity of colorectal cancer, at least in part, by regulating the p53/MADM2 pathway.
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